Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.

CONCLUSION: Panitumumab had no clinically meaningful activity in patients with metastatic RAS wild-type SBA and AAC. Our findings may relate to the primarily midgut and foregut derivation of the small bowel and ampulla.
PMID: 29259073 [PubMed - as supplied by publisher]

Source: The Oncologist - December 19, 2017 Category: Cancer & Oncology Authors: Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ Tags: Oncologist Source Type: research